SS appears to confer a distinct CRS phenotype marked by heightened symptom burden not reflected by conventional disease metrics. This discrepancy may reflect neuroinflammatory amplification driven by SS's T1/T3 cytokine profile. These findings highlight the need for symptom-focused, multidisciplinary care in this population.
Smith et al. (Tue,) studied this question.